$1.57
-0.03-1.78%
Pre-Market: Jul 3, 4:14 PM EDT
15 minutes delayed
Caribou Biosciences
CRBUNASDAQ
want to know what
the Bulls & Bears Say?
Caribou Biosciences (NASDAQ:CRBU) Stock, Analyst Ratings, Price Targets, Forecasts
Caribou Biosciences Inc has a consensus price target of $22.22 based on the ratings of 28 analysis. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Truist Securities, and HC Wainwright & Co. on June 4, 2024, May 16, 2024, and May 13, 2024, respectively. With an average price target of $17.33 between HC Wainwright & Co., Truist Securities, and HC Wainwright & Co., there's an implied 1002.98% upside for Caribou Biosciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Truist Securities
RBC Capital
Cantor Fitzgerald
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for Caribou Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/04/2024 | Buy Now | 472.7% | HC Wainwright & Co. | Robert Burns | $24 → $9 | Maintains | Buy | Get Alert |
| 05/16/2024 | Buy Now | 1109.04% | Truist Securities | Asthika Goonewardene | → $19 | Maintains | Buy | Get Alert |
| 05/13/2024 | Buy Now | 1427.2% | HC Wainwright & Co. | Robert Burns | → $24 | Reiterates | Buy → Buy | Get Alert |
| 03/19/2024 | Buy Now | 1427.2% | HC Wainwright & Co. | Robert Burns | $23 → $24 | Maintains | Buy | Get Alert |
| 03/12/2024 | Buy Now | 1109.04% | RBC Capital | Luca Issi | → $19 | Reiterates | Outperform → Outperform | Get Alert |
| 11/08/2023 | Buy Now | — | Cantor Fitzgerald | Rick Bienkowski | — | Initiates | → Neutral | Get Alert |
| 07/26/2023 | Buy Now | 1363.57% | HC Wainwright & Co. | Robert Burns | $25 → $23 | Maintains | Buy | Get Alert |
| 07/14/2023 | Buy Now | 1363.57% | Truist Securities | Asthika Goonewardene | $23 → $23 | Reiterates | Buy → Buy | Get Alert |
| 07/11/2023 | Buy Now | 1363.57% | Truist Securities | Asthika Goonewardene | → $23 | Initiates | → Buy | Get Alert |
| 05/10/2023 | Buy Now | 1490.84% | HC Wainwright & Co. | Robert Burns | $26 → $25 | Maintains | Buy | Get Alert |
| 03/14/2023 | Buy Now | 1554.47% | HC Wainwright & Co. | Robert Burns | $27 → $26 | Maintains | Buy | Get Alert |
| 03/10/2023 | Buy Now | 1109.04% | RBC Capital | Luca Issi | → $19 | Reiterates | → Outperform | Get Alert |
| 03/10/2023 | Buy Now | 1936.27% | Oppenheimer | Mark Breidenbach | $36 → $32 | Maintains | Outperform | Get Alert |
| 08/29/2022 | Buy Now | 2318.07% | Citigroup | Yigal Nochomovitz | $39 → $38 | Maintains | Buy | Get Alert |
| 08/18/2022 | Buy Now | 1618.1% | HC Wainwright & Co. | Robert Burns | $28 → $27 | Maintains | Buy | Get Alert |
| 08/10/2022 | Buy Now | 1109.04% | RBC Capital | Luca Issi | $22 → $19 | Maintains | Outperform | Get Alert |
| 05/13/2022 | Buy Now | 2381.71% | Citigroup | Yigal Nochomovitz | $29 → $39 | Maintains | Buy | Get Alert |
| 05/12/2022 | Buy Now | 2063.54% | SVB Leerink | Mani Foroohar | $30 → $34 | Maintains | Outperform | Get Alert |
| 05/10/2022 | Buy Now | 1809% | SVB Leerink | Mani Foroohar | $29 → $30 | Maintains | Outperform | Get Alert |
| 03/22/2022 | Buy Now | 1745.37% | SVB Leerink | Mani Foroohar | $32 → $29 | Maintains | Outperform | Get Alert |
| 02/18/2022 | Buy Now | 1299.94% | RBC Capital | Luca Issi | → $22 | Initiates | → Outperform | Get Alert |
| 02/14/2022 | Buy Now | 1109.04% | Brookline Capital | Leah Cann | → $19 | Initiates | → Buy | Get Alert |
| 12/01/2021 | Buy Now | 2190.8% | Oppenheimer | Mark Breidenbach | — | Initiates | → Outperform | Get Alert |
| 11/30/2021 | Buy Now | 1681.74% | HC Wainwright & Co. | Robert Burns | — | Initiates | → Buy | Get Alert |
| 11/15/2021 | Buy Now | 1618.1% | Citigroup | Yigal Nochomovitz | — | Upgrade | Neutral → Buy | Get Alert |
| 08/17/2021 | Buy Now | 1618.1% | Citigroup | Yigal Nochomovitz | — | Initiates | → Neutral | Get Alert |
| 08/17/2021 | Buy Now | 1809% | B of A Securities | — | — | Initiates | → Buy | Get Alert |
| 08/17/2021 | Buy Now | 1936.27% | SVB Leerink | Mani Foroohar | — | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Caribou Biosciences (CRBU) stock?
The latest price target for Caribou Biosciences (NASDAQ:CRBU) was reported by HC Wainwright & Co. on June 4, 2024. The analyst firm set a price target for $9.00 expecting CRBU to rise to within 12 months (a possible 472.70% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Caribou Biosciences (CRBU)?
The latest analyst rating for Caribou Biosciences (NASDAQ:CRBU) was provided by HC Wainwright & Co., and Caribou Biosciences maintained their buy rating.
When was the last upgrade for Caribou Biosciences (CRBU)?
The last upgrade for Caribou Biosciences Inc happened on November 15, 2021 when Citigroup raised their price target to $27. Citigroup previously had a neutral for Caribou Biosciences Inc.
When was the last downgrade for Caribou Biosciences (CRBU)?
There is no last downgrade for Caribou Biosciences.
When is the next analyst rating going to be posted or updated for Caribou Biosciences (CRBU)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Caribou Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Caribou Biosciences was filed on June 4, 2024 so you should expect the next rating to be made available sometime around June 4, 2025.
Is the Analyst Rating Caribou Biosciences (CRBU) correct?
While ratings are subjective and will change, the latest Caribou Biosciences (CRBU) rating was a maintained with a price target of $24.00 to $9.00. The current price Caribou Biosciences (CRBU) is trading at is $1.57, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.